With the second US Food and Drug Administration approval for its CAR-T therapy Tecartus and the company’s first approval in a leukemia setting, Kite Pharma, Inc. CEO Christi Shaw said the Gilead Sciences, Inc. cell therapy subsidiary is ready to look ahead to second priorities now that the initial priority of a full-fledged cell therapy portfolio is growing more substantial.
[Sidebar#SC144566]







